APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rofecoxib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rofecoxib Market Outlook and Growth Opportunities 2026

21 December 2025196 pages

Choose your research edition.

Industry ResearchRofecoxib Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Rofecoxib Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Rofecoxib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rofecoxib Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Rofecoxib Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Rofecoxib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rofecoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rofecoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rofecoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rofecoxib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rofecoxib market include Wuhan Xinxin Jiali Biotechnology Co. LTD, Merck, Pfizer, Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD, Chengdu Meinkai Chemical Co. LTD and Tremeau, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rofecoxib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rofecoxib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rofecoxib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rofecoxib market size, projected growth trends, production technologies, key applications, and end-use industries.

Rofecoxib Segment by Company

Wuhan Xinxin Jiali Biotechnology Co. LTD

Merck

Pfizer

Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD

Chengdu Meinkai Chemical Co. LTD

Tremeau

Rofecoxib Segment by Type

Oral Suspension.

Tablet-Form

Rofecoxib Segment by Application

Juvenile Rheumatoid Arthritis

Dysmenorrhea

Migraine

Rheumatoid Arthritis

Acute Pain Conditions

Osteoarthritis

Rofecoxib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rofecoxib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Rofecoxib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rofecoxib significant trends, drivers, influence factors in global and regions.

6. To analyze Rofecoxib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rofecoxib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rofecoxib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rofecoxib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rofecoxib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rofecoxib industry.

Chapter 3: Detailed analysis of Rofecoxib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Rofecoxib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Rofecoxib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rofecoxib Industry Trends Table 2. Rofecoxib Industry Drivers Table 3. Rofecoxib Industry Opportunities and Challenges Table 4. Rofecoxib Industry Restraints Table 5. Global Rofecoxib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rofecoxib Revenue Share by Company (2021-2026) Table 7. Global Rofecoxib Sales Volume by Company (k units) & (2021-2026) Table 8. Global Rofecoxib Sales Volume Share by Company (2021-2026) Table 9. Global Rofecoxib Average Price (US$/unit) of Company (2021-2026) Table 10. Global Rofecoxib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Rofecoxib Key Company Manufacturing Base & Headquarters Table 12. Global Rofecoxib Company, Product Type & Application Table 13. Global Rofecoxib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Rofecoxib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Suspension. Table 18. Significant Companies of Tablet-Form Table 19. Global Rofecoxib Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Rofecoxib Sales Volume by Type (2021-2026) & (k units) Table 21. Global Rofecoxib Sales Volume by Type (2027-2032) & (k units) Table 22. Global Rofecoxib Sales Volume Share by Type (2021-2026) Table 23. Global Rofecoxib Sales Volume Share by Type (2027-2032) Table 24. Global Rofecoxib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Rofecoxib Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Rofecoxib Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Rofecoxib Sales Value Share by Type (2021-2026) Table 28. Global Rofecoxib Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Juvenile Rheumatoid Arthritis Table 30. Significant Companies of Dysmenorrhea Table 31. Significant Companies of Migraine Table 32. Significant Companies of Rheumatoid Arthritis Table 33. Significant Companies of Acute Pain Conditions Table 34. Significant Companies of Osteoarthritis Table 35. Global Rofecoxib Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Rofecoxib Sales Volume by Application (2021-2026) & (k units) Table 37. Global Rofecoxib Sales Volume by Application (2027-2032) & (k units) Table 38. Global Rofecoxib Sales Volume Share by Application (2021-2026) Table 39. Global Rofecoxib Sales Volume Share by Application (2027-2032) Table 40. Global Rofecoxib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Rofecoxib Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Rofecoxib Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Rofecoxib Sales Value Share by Application (2021-2026) Table 44. Global Rofecoxib Sales Value Share by Application (2027-2032) Table 45. Global Rofecoxib Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Rofecoxib Sales by Region (2021-2026) & (k units) Table 47. Global Rofecoxib Sales Market Share by Region (2021-2026) Table 48. Global Rofecoxib Sales by Region (2027-2032) & (k units) Table 49. Global Rofecoxib Sales Market Share by Region (2027-2032) Table 50. Global Rofecoxib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Rofecoxib Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Rofecoxib Sales Value Share by Region (2021-2026) Table 53. Global Rofecoxib Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Rofecoxib Sales Value Share by Region (2027-2032) Table 55. Global Rofecoxib Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Rofecoxib Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Rofecoxib Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Rofecoxib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Rofecoxib Sales by Country (2021-2026) & (k units) Table 60. Global Rofecoxib Sales Market Share by Country (2021-2026) Table 61. Global Rofecoxib Sales by Country (2027-2032) & (k units) Table 62. Global Rofecoxib Sales Market Share by Country (2027-2032) Table 63. Global Rofecoxib Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Rofecoxib Sales Value Market Share by Country (2021-2026) Table 65. Global Rofecoxib Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Rofecoxib Sales Value Market Share by Country (2027-2032) Table 67. Wuhan Xinxin Jiali Biotechnology Co. LTD Company Information Table 68. Wuhan Xinxin Jiali Biotechnology Co. LTD Business Overview Table 69. Wuhan Xinxin Jiali Biotechnology Co. LTD Rofecoxib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Wuhan Xinxin Jiali Biotechnology Co. LTD Rofecoxib Product Portfolio Table 71. Wuhan Xinxin Jiali Biotechnology Co. LTD Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Rofecoxib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Merck Rofecoxib Product Portfolio Table 76. Merck Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Rofecoxib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Pfizer Rofecoxib Product Portfolio Table 81. Pfizer Recent Development Table 82. Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Company Information Table 83. Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Business Overview Table 84. Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Rofecoxib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Rofecoxib Product Portfolio Table 86. Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Recent Development Table 87. Chengdu Meinkai Chemical Co. LTD Company Information Table 88. Chengdu Meinkai Chemical Co. LTD Business Overview Table 89. Chengdu Meinkai Chemical Co. LTD Rofecoxib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Chengdu Meinkai Chemical Co. LTD Rofecoxib Product Portfolio Table 91. Chengdu Meinkai Chemical Co. LTD Recent Development Table 92. Tremeau Company Information Table 93. Tremeau Business Overview Table 94. Tremeau Rofecoxib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Tremeau Rofecoxib Product Portfolio Table 96. Tremeau Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Rofecoxib Distributors List Table 100. Rofecoxib Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Rofecoxib Product Image Figure 2. Global Rofecoxib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rofecoxib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Rofecoxib Sales (2021-2032) & (k units) Figure 5. Global Rofecoxib Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Rofecoxib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Suspension. Image Figure 10. Tablet-Form Image Figure 11. Global Rofecoxib Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Rofecoxib Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Rofecoxib Sales Volume Share by Type (2021-2032) Figure 14. Global Rofecoxib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Rofecoxib Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Rofecoxib Sales Value Share by Type (2021-2032) Figure 17. Juvenile Rheumatoid Arthritis Image Figure 18. Dysmenorrhea Image Figure 19. Migraine Image Figure 20. Rheumatoid Arthritis Image Figure 21. Acute Pain Conditions Image Figure 22. Osteoarthritis Image Figure 23. Global Rofecoxib Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Rofecoxib Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Rofecoxib Sales Volume Share by Application (2021-2032) Figure 26. Global Rofecoxib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Rofecoxib Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Rofecoxib Sales Value Share by Application (2021-2032) Figure 29. Global Rofecoxib Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Rofecoxib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Rofecoxib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Rofecoxib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Rofecoxib Sales Value (2021-2032) & (US$ Million) Figure 34. North America Rofecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Rofecoxib Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Rofecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Rofecoxib Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Rofecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Rofecoxib Sales Value (2021-2032) & (US$ Million) Figure 40. South America Rofecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Rofecoxib Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Rofecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Rofecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Rofecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Rofecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Rofecoxib Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Rofecoxib Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Suspension.
  • Tablet-Form
Applications
  • Juvenile Rheumatoid Arthritis
  • Dysmenorrhea
  • Migraine
  • Rheumatoid Arthritis
  • Acute Pain Conditions
  • Osteoarthritis
Companies covered
  • Wuhan Xinxin Jiali Biotechnology Co. LTD
  • Merck
  • Pfizer
  • Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
  • Chengdu Meinkai Chemical Co. LTD
  • Tremeau

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Rofecoxib Sales Value (2021-2032)
  4. 1.2.2 Global Rofecoxib Sales Volume (2021-2032)
  5. 1.2.3 Global Rofecoxib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Rofecoxib Market Dynamics
  1. 2.1 Rofecoxib Industry Trends
  2. 2.2 Rofecoxib Industry Drivers
  3. 2.3 Rofecoxib Industry Opportunities and Challenges
  4. 2.4 Rofecoxib Industry Restraints
3 Rofecoxib Market by Company
  1. 3.1 Global Rofecoxib Company Revenue Ranking in 2025
  2. 3.2 Global Rofecoxib Revenue by Company (2021-2026)
  3. 3.3 Global Rofecoxib Sales Volume by Company (2021-2026)
  4. 3.4 Global Rofecoxib Average Price by Company (2021-2026)
  5. 3.5 Global Rofecoxib Company Ranking (2024-2026)
  6. 3.6 Global Rofecoxib Company Manufacturing Base and Headquarters
  7. 3.7 Global Rofecoxib Company Product Type and Application
  8. 3.8 Global Rofecoxib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Rofecoxib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Rofecoxib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Rofecoxib Market by Type
  1. 4.1 Rofecoxib Type Introduction
  2. 4.1.1 Oral Suspension.
  3. 4.1.2 Tablet-Form
  4. 4.2 Global Rofecoxib Sales Volume by Type
  5. 4.2.1 Global Rofecoxib Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Rofecoxib Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Rofecoxib Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Rofecoxib Sales Value by Type
  9. 4.3.1 Global Rofecoxib Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Rofecoxib Sales Value by Type (2021-2032)
  11. 4.3.3 Global Rofecoxib Sales Value Share by Type (2021-2032)
5 Rofecoxib Market by Application
  1. 5.1 Rofecoxib Application Introduction
  2. 5.1.1 Juvenile Rheumatoid Arthritis
  3. 5.1.2 Dysmenorrhea
  4. 5.1.3 Migraine
  5. 5.1.4 Rheumatoid Arthritis
  6. 5.1.5 Acute Pain Conditions
  7. 5.1.6 Osteoarthritis
  8. 5.2 Global Rofecoxib Sales Volume by Application
  9. 5.2.1 Global Rofecoxib Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Rofecoxib Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Rofecoxib Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Rofecoxib Sales Value by Application
  13. 5.3.1 Global Rofecoxib Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Rofecoxib Sales Value by Application (2021-2032)
  15. 5.3.3 Global Rofecoxib Sales Value Share by Application (2021-2032)
6 Rofecoxib Regional Sales and Value Analysis
  1. 6.1 Global Rofecoxib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rofecoxib Sales by Region (2021-2032)
  3. 6.2.1 Global Rofecoxib Sales by Region: 2021-2026
  4. 6.2.2 Global Rofecoxib Sales by Region (2027-2032)
  5. 6.3 Global Rofecoxib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Rofecoxib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Rofecoxib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Rofecoxib Sales Value by Region (2027-2032)
  9. 6.5 Global Rofecoxib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Rofecoxib Sales Value (2021-2032)
  12. 6.6.2 North America Rofecoxib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Rofecoxib Sales Value (2021-2032)
  15. 6.7.2 Europe Rofecoxib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Rofecoxib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Rofecoxib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Rofecoxib Sales Value (2021-2032)
  21. 6.9.2 South America Rofecoxib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Rofecoxib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Rofecoxib Sales Value Share by Country, 2025 VS 2032
7 Rofecoxib Country-level Sales and Value Analysis
  1. 7.1 Global Rofecoxib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rofecoxib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Rofecoxib Sales by Country (2021-2032)
  4. 7.3.1 Global Rofecoxib Sales by Country (2021-2026)
  5. 7.3.2 Global Rofecoxib Sales by Country (2027-2032)
  6. 7.4 Global Rofecoxib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Rofecoxib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Rofecoxib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Rofecoxib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Rofecoxib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Rofecoxib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Rofecoxib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Rofecoxib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Rofecoxib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Rofecoxib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Rofecoxib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Rofecoxib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Rofecoxib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Rofecoxib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Rofecoxib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Rofecoxib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Rofecoxib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Rofecoxib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Rofecoxib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Rofecoxib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Rofecoxib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Rofecoxib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Rofecoxib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Rofecoxib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Rofecoxib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Rofecoxib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Rofecoxib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Rofecoxib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Rofecoxib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Rofecoxib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Rofecoxib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Rofecoxib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Rofecoxib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Rofecoxib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Rofecoxib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Rofecoxib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Rofecoxib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Rofecoxib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Rofecoxib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Rofecoxib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Rofecoxib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Rofecoxib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Rofecoxib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Rofecoxib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Rofecoxib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Rofecoxib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Rofecoxib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Rofecoxib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Rofecoxib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Rofecoxib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Rofecoxib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Rofecoxib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Rofecoxib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Rofecoxib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Rofecoxib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Rofecoxib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Rofecoxib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Rofecoxib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Rofecoxib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Rofecoxib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Rofecoxib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Rofecoxib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Rofecoxib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Rofecoxib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Rofecoxib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Rofecoxib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Rofecoxib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Rofecoxib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Rofecoxib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Rofecoxib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Rofecoxib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Rofecoxib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Rofecoxib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Rofecoxib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Rofecoxib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Rofecoxib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Rofecoxib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Rofecoxib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Rofecoxib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Rofecoxib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Rofecoxib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Rofecoxib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Rofecoxib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Rofecoxib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Rofecoxib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Rofecoxib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Rofecoxib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Wuhan Xinxin Jiali Biotechnology Co. LTD
  2. 8.1.1 Wuhan Xinxin Jiali Biotechnology Co. LTD Company Information
  3. 8.1.2 Wuhan Xinxin Jiali Biotechnology Co. LTD Business Overview
  4. 8.1.3 Wuhan Xinxin Jiali Biotechnology Co. LTD Rofecoxib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Wuhan Xinxin Jiali Biotechnology Co. LTD Rofecoxib Product Portfolio
  6. 8.1.5 Wuhan Xinxin Jiali Biotechnology Co. LTD Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Rofecoxib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Rofecoxib Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Rofecoxib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Rofecoxib Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
  20. 8.4.1 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Company Information
  21. 8.4.2 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Business Overview
  22. 8.4.3 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Rofecoxib Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Rofecoxib Product Portfolio
  24. 8.4.5 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Recent Developments
  25. 8.5 Chengdu Meinkai Chemical Co. LTD
  26. 8.5.1 Chengdu Meinkai Chemical Co. LTD Company Information
  27. 8.5.2 Chengdu Meinkai Chemical Co. LTD Business Overview
  28. 8.5.3 Chengdu Meinkai Chemical Co. LTD Rofecoxib Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Chengdu Meinkai Chemical Co. LTD Rofecoxib Product Portfolio
  30. 8.5.5 Chengdu Meinkai Chemical Co. LTD Recent Developments
  31. 8.6 Tremeau
  32. 8.6.1 Tremeau Company Information
  33. 8.6.2 Tremeau Business Overview
  34. 8.6.3 Tremeau Rofecoxib Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Tremeau Rofecoxib Product Portfolio
  36. 8.6.5 Tremeau Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rofecoxib Value Chain Analysis
  2. 9.1.1 Rofecoxib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rofecoxib Sales Mode & Process
  6. 9.2 Rofecoxib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rofecoxib Distributors
  9. 9.2.3 Rofecoxib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst